Understanding the optimal use of various therapies in life-long complex chronic diseases is vital to the present health care mission of maximizing health and minimizing costs. This K08 award proposal outlines a training and research plan to facilitate my development into an independent health services researcher focusing on the pharmaco-economics of complex chronic diseases. My main career goal is to apply health economics and decision science to inform health policy on the optimal use of various pharmaco-therapies. In the next five years, I will focus on the pharmaco-economics of biologic therapies in inflammatory bowel disease (IBD) (Crohn's disease [CD] and ulcerative colitis [UC]). Biologics are currently the most effective and most expensive therapeutic options in IBD. My project seeks to answer how biologic therapies have impacted the health and economics of IBD, and how biologics can be used more cost-effectively. This K08 award will help me accomplish the following training and career goals: (1) to acquire necessary skills in health economics and decision science to evaluate the pharmaco-economics of complex chronic diseases, (2) to become an independent health services researcher investigating the comparative cost-effectiveness of clinical strategies. To achieve these goals, I have assembled a mentoring team comprised of primary mentor, Dr. Jay Bhattacharya;co-mentor, Dr. Paul Wise;two advisors, Dr. Margaret Brandeau and Dr. Jeremy Goldhaber-Fiebert. Training will include formal courses and individual mentoring. The research goals in this proposal are motivated by the following question: Given the variety of therapeutic options and differences in IBD patient profiles, what is the best way to use biologics to sustain health and decrease costs? The project has three specific aims:
Aim 1 : To characterize the pharmaco-economics of biologics in CD and UC by determining the utilization trends and treatment effects on patient outcomes.
Aim 2 : To determine the cost-effectiveness of biologic therapies for biologic-naive CD and UC patients.
Aim 3 : To determine the health policy implications if optimal cost-effective treatment strategies were adopted in the use of biologics in CD and UC patients. I will address these aims through a large database analysis using econometric methods, two comparative cost- effectiveness analyses that compare biologics in head-to-head simulations, and two competing risk-analyses that elaborate health policy implications if cost-effective use of biologics were to become standard clinical practice.
My K08 research plan during the award term works toward developing an expertise in critically evaluating how expensive medical therapies can be used to maximize health and minimize costs for patients living with complex chronic diseases. I will use inflammatory bowel disease (IBD) as a model for complex chronic disease affecting children and adults by imposing lifelong disability and tremendous health care expenditures. The first phase of my study uses econometric techniques to analyze a large national patient database to determine health and economic impact of using biologic agents, the newest and most expensive medical therapy for the treatment of IBD. The second phase of my study builds decision analytic models to determine the cost-effectiveness of competing biologic agents. The final phase of my study uses decision science to compare health policies and benefits to society if biologic agents were used optimally. These three projects will represent pioneering efforts to advance pediatric and adult comparative cost-effectiveness research in gastroenterology and pave a path for similar investigations in other complex chronic diseases.
|Park, K T; Sceats, L; Dehghan, M et al. (2018) Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther 48:340-346|
|Barfield, Elaine; Sockolow, Robbyn; Hoffenberg, Edward et al. (2018) Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 66:680-686|
|Yu, H; MacIsaac, D; Wong, J J et al. (2018) Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther 47:364-370|
|Sellers, Zachary M; MacIsaac, Donna; Yu, Helen et al. (2018) Nationwide Trends in Acute and Chronic Pancreatitis Among Privately Insured Children and Non-Elderly Adults in the United States, 2007-2014. Gastroenterology 155:469-478.e1|
|Piester, Travis; Frymoyer, Adam; Christofferson, Megan et al. (2018) A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease. Inflamm Bowel Dis 24:227-234|
|Picoraro, Joseph; Winberry, Gabriel; Siegel, Corey A et al. (2017) Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Inflamm Bowel Dis 23:174-180|
|Hutsell, Stephanie Q; Wu, May; Park, K T (2017) Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications. J Pediatr Gastroenterol Nutr 65:430-431|
|Patel, Dimple; Park, K T (2017) Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings. J Pediatr Gastroenterol Nutr 65:134-136|
|Park, K T; Heida, Anke; van Rheenen, Patrick F (2017) Standardizing Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 23:E47|
|Frymoyer, Adam; Hoekman, Daniël R; Piester, Travis L et al. (2017) Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. J Pediatr Gastroenterol Nutr 65:639-645|
Showing the most recent 10 out of 29 publications